JVMAX
Price
$28.64
Change
+$0.32 (+1.13%)
Updated
Dec 20 closing price
SAMVX
Price
$11.68
Change
+$0.14 (+1.21%)
Updated
Dec 20 closing price
Ad is loading...

JVMAX vs SAMVX

Header iconJVMAX vs SAMVX Comparison
Open Charts JVMAX vs SAMVXBanner chart's image
JHancock Disciplined Value Mid Cap A
Price$28.64
Change+$0.32 (+1.13%)
VolumeN/A
CapitalizationN/A
Virtus Ceredex Mid-Cap Value Equity A
Price$11.68
Change+$0.14 (+1.21%)
VolumeN/A
CapitalizationN/A
JVMAX vs SAMVX Comparison Chart
Loading...
View a ticker or compare two or three
VS
JVMAX vs. SAMVX commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JVMAX is a Buy and SAMVX is a Hold.

FUNDAMENTALS
Fundamentals
JVMAX has more cash in the bank: 20.3B vs. SAMVX (1.69B). SAMVX pays higher dividends than JVMAX: SAMVX (0.84) vs JVMAX (0.67). JVMAX was incepted earlier than SAMVX: JVMAX (28 years) vs SAMVX (21 years). SAMVX is a more actively managed with annual turnover of: 140.00 vs. JVMAX (41.00). JVMAX has a lower initial minimum investment than SAMVX: JVMAX (1000) vs SAMVX (2500). SAMVX annual gain was more profitable for investors over the last year : 3.28 vs. JVMAX (-0.72). JVMAX return over 5 years is better than : 21.41 vs. SAMVX (-4.88).
JVMAXSAMVXJVMAX / SAMVX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence28 years21 years-
Gain YTD-1.4412.204-65%
Front LoadN/AN/A-
Min. Initial Investment1000250040%
Min. Initial Investment IRAN/AN/A-
Net Assets20.3B1.69B1,204%
Annual Yield % from dividends0.670.8480%
Returns for 1 year-0.723.28-22%
Returns for 3 years1.07-21.07-5%
Returns for 5 years21.41-4.88-439%
Returns for 10 years34.67-8.74-397%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WFC70.341.49
+2.16%
Wells Fargo & Co
KAR20.29N/A
N/A
OPENLANE
G42.19-0.11
-0.26%
Genpact Limited
ZVRA8.49-0.05
-0.59%
Zevra Therapeutics
CNTX1.02-0.07
-6.42%
Context Therapeutics